Clincosm LogoSign in Get a demo

MERCURE: Metalloproteinases and Recurrent Corneal Erosion Syndrome

Sponsor
Fondation Ophtalmologique Adolphe de Rothschild (Other)
Overall Status
Completed
CT.gov ID
NCT02891694
Collaborator
(none)
19
Enrollment
1
Location
47.8
Actual Duration (Months)
0.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Recurrent corneal erosion (RCE) syndrome can be observed either in the context of a dystrophy of the basement membrane or following corneal trauma. This syndrome is characterized by recurrent episodes of ocular pain more or less associated with localized separations between the outer epithelium and the epithelial basal lamina (basement membrane) because of anchorage abnormalities between these two corneal layers. This could be the result of an increased expression of metalloproteinases cleaving the hemidesmosomes which anchor epithelium to the basement membrane.

The investigators hypothesis is that episodes of RCEs are favored by a hyper- expression of matricial metalloprotease 9 (MMP-9) induced by EMMPRIN and Galectin-3. The identification of such induction could lead to development of therapeutics inhibiting EMMPRIN and Galectin- 3 in the RCE syndrome.

Condition or Disease Intervention/Treatment Phase
  • Other: in vitro immuno-histo-chemical analysis of corneal epithelium

Study Design

Study Type:
Observational
Actual Enrollment :
19 participants
Observational Model:
Other
Time Perspective:
Cross-Sectional
Actual Study Start Date :
Dec 2, 2016
Actual Primary Completion Date :
Jun 26, 2020
Actual Study Completion Date :
Nov 26, 2020

Arms and Interventions

Arm Intervention/Treatment
recurrent corneal erosion

Other: in vitro immuno-histo-chemical analysis of corneal epithelium
control patients (refractive surgery)

Other: in vitro immuno-histo-chemical analysis of corneal epithelium

Outcome Measures

Primary Outcome Measures

  1. expression of the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) in epithelial cells [baseline]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Age > 18 years old

  • Recurrent Corneal Erosion Syndrome, with - failure of medical treatment and therapeutic photokeratectomy scheduled

  • Photorefractive surgical keratectomy (control patients)

Exclusion Criteria:

  • Opposition to participation in the study

  • Known pregnancy or breast-feeding patient

  • No medical insurance coverage

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fondation Opthalmologique A de Rothschild Paris France 75019

Sponsors and Collaborators

  • Fondation Ophtalmologique Adolphe de Rothschild

Investigators

  • Principal Investigator: Eric GABISON, MD, PhD, Fondation OPH A de Rothschild

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fondation Ophtalmologique Adolphe de Rothschild
ClinicalTrials.gov Identifier:
NCT02891694
Other Study ID Numbers:
  • EGN_2016_8
First Posted:
Sep 7, 2016
Last Update Posted:
Dec 10, 2020
Last Verified:
Dec 1, 2020
Additional relevant MeSH terms:
Syndrome

Study Results

No Results Posted as of Dec 10, 2020